China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totaling 721,044 shares, an increase of 999.1% from the September 30th total of 65,603 shares. Currently, 157.1% of the company’s shares are short sold. Based on an average daily volume of 52,120,891 shares, the days-to-cover ratio is currently 0.0 days.
China SXT Pharmaceuticals Stock Performance
Shares of SXTC stock traded down $0.12 on Tuesday, reaching $3.42. 89,351 shares of the company were exchanged, compared to its average volume of 68,124. The company has a 50-day moving average of $209.45 and a 200-day moving average of $37,799.87. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.94 and a quick ratio of 7.76. China SXT Pharmaceuticals has a one year low of $3.28 and a one year high of $8,375,880.00.
Analyst Ratings Changes
SXTC has been the topic of a number of research analyst reports. Wall Street Zen upgraded China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings upgraded shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has a consensus rating of “Sell”.
Check Out Our Latest Report on SXTC
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc (NASDAQ: SXTC) is a pharmaceutical company based in Taizhou, Jiangsu Province, China. The company develops, manufactures and sells traditional Chinese medicine products, serving customers primarily in the Chinese market.
Its product portfolio includes prescription and over-the-counter traditional Chinese medicines, as well as health-related products and dietary supplements. The company’s operations encompass the preparation of herbal ingredients and the production, marketing and distribution of finished traditional Chinese medicine products.
China SXT Pharmaceuticals was established in 2005 and completed its initial public offering on the Nasdaq Capital Market in 2019.
Featured Articles
- Five stocks we like better than China SXT Pharmaceuticals
- Approaching Earnings Season, Are Pure Play Quantum Stocks Still a Good Bet?
- Lockheed Martin’s F-35 Deal Could Change How Wall Street Values the Stock
- Merck and Moderna’s Cancer Vaccine Worked—Who Gets Paid?
- Intel’s $155 Price Target Raises a Bigger Question About Its Turnaround Potential
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
